KDR and differentiated thyroid carcinoma: In conclusion, these findings highlight 17.3.1.7.8 and BMC_0005 compounds as compelling candidates for VEGFR-2 inhibition, offering a promising therapeutic avenue for papillary thyroid carcinoma, warranting further in vitro and in vivo validation for potential therapeutic use.